Sanofi and C4X Discovery enter licensing deal worth up to €414m
Sanofi and drug discovery company C4X Discovery (C4XD) have entered an exclusive worldwide licensing agreement worth up to €414m for C4XD’s oral pre-clinical IL-17A inhibitor programme.
deal
Komodo Health secures $220m in Series E funding round
Health analytics start-up Komodo Health has closed a $220m Series E funding round, giving the...
Federal Trade Commission forms multilateral working group on pharma mergers
The US Federal Trade Commission (FTC) has launched a multilateral working group with domestic and international partners to reassess their...
Q&A: staving off AMR disaster with Ineos and the University of Oxford
The University of Oxford has teamed up with manufacturing company Ineos to open up a £100m institute focused on AMR...
Merck-Pandion acquisition: re-balancing immune response to treat autoimmune disease
Merck has acquired Pandion Therapeutics for $1.85bn. The deal centres around Pandion’s TALON technology and immune modulators, which re-balance the...
Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing
Precision immunology company ImmuneID has launched with $17m in funding. The financing round was led by founding investor Longwood Fund; other investors participating in the round include XFund and Arch…
Precision medicine in AMD: SPAC merger sees Gemini make its public debut
Precision medicine-focused Gemini Therapeutics has completed a business combination transaction with Foresite Capital’s special purpose acquisition company (SPAC) FS Development Corp (FSDC). The deal was initiated in October 2021 and…
Humacyte agrees SPAC merger to go public with bioengineered tissue tech
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC). The deal allows Humacyte to become a…
Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors
Eli Lilly and Company and Rigel Pharmaceuticals have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialise the latter’s receptor-interacting serine / threonine-protein kinase 1…
Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake
Belgium-based Imcyse has closed a €21.3m ($25.8m) Series B round. Investors participating in the round included Société Fédérale de Participations et d'Investissement (SFPI), Biogenosis and Katholieke Universiteit Leuven (KUL), the…
GSK, Vir expand collaboration for influenza, respiratory virus therapies
GlaxoSmithKline (GSK) has signed a binding agreement with Vir Biotechnology to expand its existing partnership to research and develop novel therapies for influenza and other respiratory viruses. Last April, the…
